Literature DB >> 33239444

Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1.

Lynn N Bertagnolli1, Joseph Varriale1, Sarah Sweet1, Jacqueline Brockhurst1, Francesco R Simonetti1, Jennifer White1, Subul Beg1, Kenneth Lynn2, Karam Mounzer3, Ian Frank2, Pablo Tebas2, Katharine J Bar2, Luis J Montaner4, Robert F Siliciano5,6, Janet D Siliciano1.   

Abstract

In untreated HIV-1 infection, rapid viral evolution allows escape from immune responses. Viral replication can be blocked by antiretroviral therapy. However, HIV-1 persists in a latent reservoir in resting CD4+ T cells, and rebound viremia occurs following treatment interruption. The reservoir, which is maintained in part by clonal expansion, can be measured using quantitative viral outgrowth assays (QVOAs) in which latency is reversed with T cell activation to allow viral outgrowth. Recent studies have shown that viruses detected in QVOAs prior to treatment interruption often differ from rebound viruses. We hypothesized that autologous neutralizing antibodies directed at the HIV-1 envelope (Env) protein might block outgrowth of some reservoir viruses. We modified the QVOA to reflect pressure from low concentrations of autologous antibodies and showed that outgrowth of a substantial but variable fraction of reservoir viruses is blocked by autologous contemporaneous immunoglobulin G (IgG). A reduction in outgrowth of >80% was seen in 6 of 15 individuals. This effect was due to direct neutralization. We established a phylogenetic relationship between rebound viruses and viruses growing out in vitro in the presence of autologous antibodies. Some large infected cell clones detected by QVOA carried neutralization-sensitive viruses, providing a cogent explanation for differences between rebound virus and viruses detected in standard QVOAs. Measurement of the frequency of reservoir viruses capable of outgrowth in the presence of autologous IgG might allow more accurate prediction of time to viral rebound. Ultimately, therapeutic immunization targeting the subset of variants resistant to autologous IgG might contribute to a functional cure.

Entities:  

Keywords:  HIV; QVOA; latency; neutralizing antibody; reservoir

Mesh:

Substances:

Year:  2020        PMID: 33239444      PMCID: PMC7749285          DOI: 10.1073/pnas.2020617117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  82 in total

1.  Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

Authors:  M C Strain; H F Günthard; D V Havlir; C C Ignacio; D M Smith; A J Leigh-Brown; T R Macaranas; R Y Lam; O A Daly; M Fischer; M Opravil; H Levine; L Bacheler; C A Spina; D D Richman; J K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-08       Impact factor: 11.205

Review 2.  The Molecular Basis for Human Immunodeficiency Virus Latency.

Authors:  Uri Mbonye; Jonathan Karn
Journal:  Annu Rev Virol       Date:  2017-07-17       Impact factor: 10.431

3.  Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane.

Authors:  Zheng Wang; Evelyn E Gurule; Timothy P Brennan; Jeffrey M Gerold; Kyungyoon J Kwon; Nina N Hosmane; Mithra R Kumar; Subul A Beg; Adam A Capoferri; Stuart C Ray; Ya-Chi Ho; Alison L Hill; Janet D Siliciano; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-26       Impact factor: 11.205

4.  Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.

Authors:  Justin R Bailey; Ahmad R Sedaghat; Tara Kieffer; Timothy Brennan; Patricia K Lee; Megan Wind-Rotolo; Christine M Haggerty; Ashrit R Kamireddi; Yi Liu; Jessica Lee; Deborah Persaud; Joel E Gallant; Joseph Cofrancesco; Thomas C Quinn; Claus O Wilke; Stuart C Ray; Janet D Siliciano; Richard E Nettles; Robert F Siliciano
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

6.  Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy.

Authors:  Timothy J Henrich; Kristen S Hobbs; Emily Hanhauser; Eileen Scully; Louise E Hogan; Yvonne P Robles; Kaitlyn S Leadabrand; Francisco M Marty; Christine D Palmer; Stephanie Jost; Christian Körner; Jonathan Z Li; Rajesh T Gandhi; Ayad Hamdan; Jeremy Abramson; Ann S LaCasce; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

7.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

8.  Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

Authors:  Katharine J Bar; Michael C Sneller; Linda J Harrison; J Shawn Justement; Edgar T Overton; Mary E Petrone; D Brenda Salantes; Catherine A Seamon; Benjamin Scheinfeld; Richard W Kwan; Gerald H Learn; Michael A Proschan; Edward F Kreider; Jana Blazkova; Mark Bardsley; Eric W Refsland; Michael Messer; Katherine E Clarridge; Nancy B Tustin; Patrick J Madden; KaSaundra Oden; Sijy J O'Dell; Bernadette Jarocki; Andrea R Shiakolas; Randall L Tressler; Nicole A Doria-Rose; Robert T Bailer; Julie E Ledgerwood; Edmund V Capparelli; Rebecca M Lynch; Barney S Graham; Susan Moir; Richard A Koup; John R Mascola; James A Hoxie; Anthony S Fauci; Pablo Tebas; Tae-Wook Chun
Journal:  N Engl J Med       Date:  2016-11-09       Impact factor: 91.245

9.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.

Authors:  T W Chun; D Engel; M M Berrey; T Shea; L Corey; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

10.  Evaluating Clonal Expansion of HIV-Infected Cells: Optimization of PCR Strategies to Predict Clonality.

Authors:  Sarah B Laskey; Christopher W Pohlmeyer; Katherine M Bruner; Robert F Siliciano
Journal:  PLoS Pathog       Date:  2016-08-05       Impact factor: 6.823

View more
  11 in total

Review 1.  Viral and Host Biomarkers of HIV Remission Post Treatment Interruption.

Authors:  Leila B Giron; Mohamed Abdel-Mohsen
Journal:  Curr HIV/AIDS Rep       Date:  2022-04-19       Impact factor: 5.071

Review 2.  An ordeal that does not heal: understanding barriers to a cure for HIV-1 infection.

Authors:  Mathias Lichterfeld; Ce Gao; Xu G Yu
Journal:  Trends Immunol       Date:  2022-08       Impact factor: 19.709

Review 3.  Role of Early Life Cytotoxic T Lymphocyte and Natural Killer Cell Immunity in Paediatric HIV Cure/Remission in the Anti-Retroviral Therapy Era.

Authors:  Vinicius A Vieira; Nicholas Herbert; Gabriela Cromhout; Emily Adland; Philip Goulder
Journal:  Front Immunol       Date:  2022-05-11       Impact factor: 8.786

4.  Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation.

Authors:  Yijia Li; Behzad Etemad; Ruth Dele-Oni; Radwa Sharaf; Ce Gao; Mathias Lichterfeld; Jonathan Z Li
Journal:  AIDS       Date:  2021-06-01       Impact factor: 4.632

5.  Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection.

Authors:  Julie L Mitchell; Justin Pollara; Kenneth Dietze; R Whitney Edwards; Junsuke Nohara; Kombo F N'guessan; Michelle Zemil; Supranee Buranapraditkun; Hiroshi Takata; Yifan Li; Roshell Muir; Eugene Kroon; Suteeraporn Pinyakorn; Shalini Jha; Sopark Manasnayakorn; Suthat Chottanapund; Pattarawat Thantiworasit; Peeriya Prueksakaew; Nisakorn Ratnaratorn; Bessara Nuntapinit; Lawrence Fox; Sodsai Tovanabutra; Dominic Paquin-Proulx; Lindsay Wieczorek; Victoria R Polonis; Frank Maldarelli; Elias K Haddad; Praphan Phanuphak; Carlo P Sacdalan; Morgane Rolland; Nittaya Phanuphak; Jintanat Ananworanich; Sandhya Vasan; Guido Ferrari; Lydie Trautmann
Journal:  J Clin Invest       Date:  2022-01-04       Impact factor: 14.808

Review 6.  The Clonal Expansion Dynamics of the HIV-1 Reservoir: Mechanisms of Integration Site-Dependent Proliferation and HIV-1 Persistence.

Authors:  Yang-Hui Jimmy Yeh; Kerui Yang; Anya Razmi; Ya-Chi Ho
Journal:  Viruses       Date:  2021-09-17       Impact factor: 5.818

7.  Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence.

Authors:  Michel C Nussenzweig; Lillian B Cohn; Amy S Huang; Victor Ramos; Thiago Y Oliveira; Christian Gaebler; Mila Jankovic
Journal:  J Exp Med       Date:  2021-10-12       Impact factor: 14.307

8.  Prolonged viral suppression with anti-HIV-1 antibody therapy.

Authors:  Marina Caskey; Michel C Nussenzweig; Christian Gaebler; Lilian Nogueira; Elina Stoffel; Thiago Y Oliveira; Gaëlle Breton; Katrina G Millard; Martina Turroja; Allison Butler; Victor Ramos; Michael S Seaman; Jacqueline D Reeves; Christos J Petroupoulos; Irina Shimeliovich; Anna Gazumyan; Caroline S Jiang; Nikolaus Jilg; Johannes F Scheid; Rajesh Gandhi; Bruce D Walker; Michael C Sneller; Anthony Fauci; Tae-Wook Chun
Journal:  Nature       Date:  2022-04-13       Impact factor: 69.504

9.  Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir.

Authors:  Taina T Immonen; Christine M Fennessey; Leslie Lipkey; Abigail Thorpe; Gregory Q Del Prete; Jeffrey D Lifson; Miles P Davenport; Brandon F Keele
Journal:  PLoS Pathog       Date:  2021-06-18       Impact factor: 6.823

10.  Characterizing the Relationship Between Neutralization Sensitivity and env Gene Diversity During ART Suppression.

Authors:  Andrew Wilson; Leyn Shakhtour; Adam Ward; Yanqin Ren; Melina Recarey; Eva Stevenson; Maria Korom; Colin Kovacs; Erika Benko; R Brad Jones; Rebecca M Lynch
Journal:  Front Immunol       Date:  2021-09-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.